Lipid formulations of amphotericin

被引:13
|
作者
Botero, Martha C. [1 ]
Puentes-Herrera, Marcela [1 ]
Cortes, Jorge A. [2 ]
机构
[1] Univ Nacl Colombia, Fac Med, Dept Med Interna, Bogota, Colombia
[2] Univ Nacl Colombia, Grp Invest Enfermedades Infecciosas, Bogota, Colombia
来源
REVISTA CHILENA DE INFECTOLOGIA | 2014年 / 31卷 / 05期
关键词
Amphotericin B; fungemia; drug toxicity; histoplasmosis; aspergillosis; candidemia; candidiasis; invasive; cryptococcosis; zygomycosis; leishmaniasis; MULTICENTER RANDOMIZED-TRIAL; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; HEMATOLOGIC MALIGNANCIES; DOUBLE-BLIND; VISCERAL LEISHMANIASIS; INVASIVE ASPERGILLOSIS; ANTIFUNGAL THERAPY; SALVAGE THERAPY; B AMBISOME;
D O I
10.4067/S0716-10182014000500002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Amphotericin B deoxycholate use has increased during the past years in parallel with the increase in the number of immunosuppressed patients suffering invasive fungal infections. This drug is associated with a high rate of side effects, especially renal toxicity. Lipid formulations (liposomal, lipid complex, colloidal suspension and the Indian liposomal formulation) have been developed, which share the same antifungal spectrum but differ in efficacy and toxicity. A review of amphotericin lipid formulations is presented, focusing on differences in efficacy and, especially renal toxicity. The main problem for use of these formulations in Latin America is their highcost.
引用
收藏
页码:518 / 527
页数:10
相关论文
共 50 条
  • [42] Anaphylaxis upon switching lipid-containing amphotericin B formulations
    Kauffman, CA
    Wiseman, SW
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (05) : 1237 - 1238
  • [43] Lipid formulations for amphotericin B: Does the emperor need new clothes?
    Graybill, JP
    ANNALS OF INTERNAL MEDICINE, 1996, 124 (10) : 921 - 923
  • [44] Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence
    Bellmann, R
    Egger, P
    Wiedermann, CJ
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (11) : 1500 - 1501
  • [45] Lipid formulations of amphotericin B as first-line treatment of zygomycosis
    Petrikkos, G. L.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 : 87 - 92
  • [46] AMPHOTERICIN B LIPID FORMULATIONS: COST SIMULATION WITH REAL WORLD DATA
    Sartori, D. P.
    Viana, A.
    Vieira, J. B.
    Romero, J. F.
    Albuquerque, I. M.
    Neto, V. D.
    Mattos, T. C.
    VALUE IN HEALTH, 2017, 20 (09) : A928 - A928
  • [48] Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia - Reply
    Hughes, W
    Armstrong, D
    Bodey, G
    Bow, E
    Brown, A
    Calandra, T
    Feld, R
    Pizzo, P
    Rolston, K
    Shenep, J
    Young, L
    CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) : 897 - 898
  • [49] Lipid-based amphotericin B formulations: from animals to man
    Bekersky, I
    Fielding, RM
    Buell, D
    Lawrence, I
    PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (06): : 230 - 236
  • [50] Anaphylaxis upon switching lipid-containing amphotericin B formulations
    Cronin, JE
    Barron, RL
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (06) : 1342 - 1342